ClinicalTrials.gg
CompletedNCT01355367Updated Jan 29, 2014

High Dose BAYA1040 CR: a Long Term Extension Study

A Phase 3 interventional study of Nifedipine (Adalat, BAYA1040) in Hypertension, sponsored by Bayer. Completed at 22 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-01-29.

Primary conditionEssential HypertensionRegistry: HypertensionReclassifiedWhy we changed it
Registry
Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Essential Hypertension
Why
  1. The study's title name Essential Hypertension, a narrower term within Hypertension.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Essential Hypertension with a site in Japan — 1 open to participants now, 1 under way, none of them phase 3. Essential Hypertension · Japan.

Enrollment
17th of 26
120 · median 304
Started
2011
with 3 others
Phase 3
11 of 27
none open now
Registered
16th of 27
by date
Lead sponsor
3 of 27
Bayer

Among the 27 studies in Essential Hypertension with a site in Japan, this one is the 17th largest by enrollment of the 26 interventional ones that give a count, is one of 4 that started in 2011, is one of 11 in phase 3, and was the 16th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

1 of the 27 studies in Essential Hypertension with a site in Japan is open now. Recruiting first, the newest first:

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 44 Essential Hypertension studies recruiting now, 16 (36%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Essential Hypertension with a site in Japan, or all of them as a file.
02

Study summary

This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040 CR 80 mg/day (40 mg twice daily) in patients with essential hypertension for whom the test drug is tolerable during the 8 week double blind treatment phase of Study 13176.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • BAYA1040 CR
  • Nifedipine
  • Essential hypertension
  • Japanese Patients
  • Phase III
  • Extension study
04

In context

Essential Hypertension Reclassified

480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

This study's enrollment of 120 is below the median of 144 across 406 interventional studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who complete the 8 week double blind treatment phase of Study 13176 and for whom the test drug is tolerable

Exclusion criteria

Exclusion Criteria:

  • Patients with expected difficulties for the continuous 1 year follow up
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Nifedipine (Adalat, BAYA1040)

Interventions

07

What researchers measure

Primary outcomes

  1. Safety variables will be summarized using descriptive statistics based on adverse events collection

    Time frame: Week 52

Secondary outcomes

  1. Changes from baseline in diastolic blood pressure (DBP) while sitting

    Time frame: Baseline, week 10, 12, 16, 24, 28, 32, 36, 40, 44, 48 and 52

  2. Changes from baseline in systolic blood pressure (SBP) while sitting

    Time frame: Baseline, week 10, 12, 16, 24, 28, 32, 36, 40, 44, 48 and 52

  3. Proportion of subjects achieving a target BP based on the Japanese Society of Hypertension (JSH) 2009 guidelines

    Time frame: Baseline, week 10, 12, 16, 24, 28, 32, 36, 40, 44, 48 and 52

  4. Proportion of subjects achieving a target DBP and SBP based on JSH 2009 guidelines or a >10 mmHg reduction of DBP

    Time frame: Baseline, week 10, 12, 16, 24, 28, 32, 36, 40, 44, 48 and 52

08

Study locations

22 sites
  • Hirosaki, Aomori 036-8082, Japan
  • Kamagaya, Chiba 273-0100, Japan
  • Asahikawa, Hokkaido 070-0061, Japan
  • Asahikawa, Hokkaido 078-8214, Japan
  • Sapporo, Hokkaido 003-0026, Japan
  • Sapporo, Hokkaido 003-0825, Japan
  • Sapporo, Hokkaido 004-0004, Japan
  • Sapporo, Hokkaido 007-0841, Japan
  • Sapporo, Hokkaido 062-0053, Japan
  • Sapporo, Hokkaido 063-0841, Japan
  • Sapporo, Hokkaido 064-0803, Japan
  • Sapporo, Hokkaido 064-0807, Japan
  • Kawasaki, Kanagawa 210-0852, Japan
  • Daito, Osaka 574-0074, Japan
  • Kishiwada, Osaka 596-8522, Japan
  • Yao, Osaka 581-0011, Japan
  • Tokorozawa, Saitama 359-1141, Japan
  • Hachioji, Tokyo 192-0046, Japan
  • Meguro, Tokyo 152-0031, Japan
  • Minato, Tokyo 105-7390, Japan
  • Minato, Tokyo 108-0075, Japan
  • Shizuoka, 421-0193, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Sep 2011 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2011
First posted
May 18, 2011
Start
Jan 2011
Primary completionActual
Sep 2011
CompletionActual
Apr 2012
Last update
Jan 29, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01355367
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 18, 2011
Start date
Jan 2011
Primary completion
Sep 2011
Completion
Apr 2012
Last update
Jan 29, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nifedipine

Start the discussion